日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy

ADAPT学习型癌症治疗系统:ARPA-H旨在革新癌症治疗的计划

Bild, Andrea H; Sangar, Michelle C; McQuerry, Jasmine A; Ideker, Trey; Kopetz, Scott; Carey, Lisa; Nath, Aritro; Marcus, Daniel; Regier, Allison; Rashid, Naim; Barzilay, Regina; Winer, Eric; Salgia, Ravi; Malhotra, Jyoti; Gentles, Andrew; Buetow, Kenneth; Mahmood, Faisal; Markman, David W; Eddy, James A

Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis

脱细胞细胞外基质支架用于构建微小结直肠癌肝转移的休眠状态

VandenHeuvel, Sabrina N; Nash, Lucia L; Clevenger, Abigail J; Collier, Claudia A; Benavides, Oscar R; Roy, Sanjana; Goggans, Brinlee; Salikhova, Aelita; Tharakesh, Anvitha; Haricharan, Svasti; Stratman, Amber N; Kopetz, Scott; Walsh, Alex J; Raghavan, Shreya A

Surgical and nonsurgical treatment of hip and knee osteoarthritis: a 2026 perspective

髋关节和膝关节骨关节炎的手术和非手术治疗:2026 年展望

Lou, Emil; Beg, Shaalan; Bergsland, Emily; Eng, Cathy; Khorana, Alok; Kopetz, Scott; Lubner, Sam; Saltz, Leonard; Shankaran, Veena; Zafar, S Yousuf; LAIGAARD, Jens; MALEITZKE, Tazio; SKOU, Søren T; MECHLENBURG, Inger; BANDHOLM, Thomas; BERG, Lise C; OVERGAARD, Søren

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

恩科拉非尼、西妥昔单抗和mFOLFOX6治疗BRAF突变型结直肠癌

Elez, Elena; Yoshino, Takayuki; Shen, Lin; Lonardi, Sara; Van Cutsem, Eric; Eng, Cathy; Kim, Tae Won; Wasan, Harpreet Singh; Desai, Jayesh; Ciardiello, Fortunato; Yaeger, Rona; Maughan, Timothy S; Morris, Van K; Wu, Christina; Usari, Tiziana; Laliberte, Robert; Dychter, Samuel S; Zhang, Xiaosong; Tabernero, Josep; Kopetz, Scott

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

恩科拉非尼、西妥昔单抗和化疗治疗BRAF突变型结直肠癌:一项随机3期试验

Kopetz, Scott; Yoshino, Takayuki; Van Cutsem, Eric; Eng, Cathy; Kim, Tae Won; Wasan, Harpreet Singh; Desai, Jayesh; Ciardiello, Fortunato; Yaeger, Rona; Maughan, Timothy S; Beyzarov, Elena; Zhang, Xiaoxi; Ferrier, Graham; Zhang, Xiaosong; Tabernero, Josep

Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial

Precemtabart tocentecan(一种抗CEACAM5抗体药物偶联物)治疗转移性结直肠癌:一项I期临床试验

Kopetz, Scott; Boni, Valentina; Kato, Ken; Raghav, Kanwal P S; Vieito, Maria; Pallis, Athanasios; Habermehl, Christina; Siddiqui, Abdul; Courlet, Perrine; Sloot, Willem; Raab-Westphal, Sabine; Hart, Felix; Rodriguez-Rivera, Ildefonso

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF(V600E) metastatic colorectal cancer

恩科拉非尼、西妥昔单抗和纳武利尤单抗治疗微卫星稳定型BRAF(V600E)转移性结直肠癌的I/II期临床试验

Morris, Van K; Parseghian, Christine M; Bahrambeigi, Vahid; Abdelfattah, Nourhan; Xiao, Lianchun; Agrawal, Anjali; Lin, Kangyu; Raghav, Kanwal P S; Wolff, Robert A; Dasari, Arvind; Huey, Ryan W; Kee, Bryan K; Overman, Michael J; Willis, Jason A; Le, Phat H; Escano, Michelle; Baig, Yunyu C; Pan, Kelsey; Menter, David; Tam, Alda L; Foo, Wai C; Shen, Li; Lee, Hey Min; Gallup, Thomas D; Margain, Cori; Gallup, Dave; Rajapakshe, Kimal I; Guerrero, Paola A; Wang, Jing; Corcoran, Ryan B; Maitra, Anirban; Yun, Kyuson; Kopetz, Scott

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

曲妥珠单抗联合帕妥珠单抗对比西妥昔单抗联合伊立替康治疗 RAS/BRAF 野生型、HER2 阳性转移性结直肠癌患者(S1613):一项随机 II 期试验

Raghav, Kanwal Pratap Singh; Guthrie, Katherine A; Tan, Benjamin Jr; Denlinger, Crystal S; Fakih, Marwan; Overman, Michael J; Dasari, N Arvind; Corum, Larry R; Hicks, Lee G; Patel, Mital S; Esparaz, Benjamin T; Kazmi, Syed M; Alluri, Nitya; Colby, Sarah; Gholami, Sepideh; Gold, Philip J; Chiorean, E Gabriela; Kopetz, Scott; Hochster, Howard S; Philip, Philip A

Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial

软件评估与视觉评估在接受经皮热消融治疗的肝肿瘤患者中最小消融边缘的比较(COVER-ALL):一项随机 II 期试验

Odisio, Bruno C; Albuquerque, Jessica; Lin, Yuan-Mao; Anderson, Brian M; O'Connor, Caleb S; Rigaud, Bastien; Briones-Dimayuga, Maria; Jones, Aaron K; Fellman, Bryan M; Huang, Steven Y; Kuban, Joshua; Metwalli, Zeyad A; Sheth, Rahul; Habibollahi, Peiman; Patel, Milan; Shah, Ketan Y; Cox, Veronica L; Kang, HyunSeon C; Morris, Van K; Kopetz, Scott; Javle, Milind M; Kaseb, Ahmed; Tzeng, Ching-Wei; Cao, Hop-Tran; Newhook, Timothy; Chun, Yun Shin; Vauthey, Jean-Nicolas; Gupta, Sanjay; Paolucci, Iwan; Brock, Kristy K

Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.

直接抑制 RAS 揭示了由 RAS G12 和 Q61 突变驱动的致癌信号的特征

Marasco Michelangelo, Kumar Dinesh, Garcia Borrego Santiago, Seale Tessa, Maddalena Giulia, Mezzadra Riccardo, Belanger Kylie, Cole Soren, Perez Brayan, Luan Wei, Mukherjee Radha, Aricescu Ilinca, Markov Vladimir, Zhu Yuxin, Arena Sabrina, Bardelli Alberto, de Stanchina Elisa, Lowe Scott W, Burkhart Richard A, Zimmerman Jacquelyn W, Yaeger Rona, Kopetz Scott E, Rosen Neal, Misale Sandra